

Review

Crim1–, a regulator of developmental organogenesis

Swati Iyer¹, David J. Pennisi¹ and Michael Piper^{1,2}¹School of Biomedical Sciences and ²Queensland Brain Institute, The University of Queensland, Brisbane, Australia

Summary. The regulation of growth factor localization, availability and activity is critical during embryogenesis to ensure appropriate organogenesis. This process is regulated through the coordinated expression of growth factors and their cognate receptors, as well as via proteins that can bind, sequester or localize growth factors to distinct locations. One such protein is the transmembrane protein Crim1. This protein has been shown to be expressed broadly within the developing embryo, and to regulate organogenesis within the eye, kidney and placenta. Mechanistically, Crim1 has been revealed to mediate organogenesis via its interaction with growth factors including TGFβs, BMPs, VEGFs and PDGFs. More recently, Crim1 has been shown to influence cardiac development, providing further insights into the function of this protein. This review will provide an overview of the role of Crim1 in organogenesis, largely focusing on how this protein regulates growth factor signaling in the nascent heart. Moreover, we will address the challenges ahead relating to further elucidating how Crim1 functions during development.

Key words: Kidney, Placenta, Lens, Retina, Nervous system, Heart

Introduction

Cysteine-Rich Transmembrane BMP Regulator-1 (Crim1) is a novel, N-glycosylated transmembrane protein encoded by the *Crim1* gene (Kolle et al., 2000;

Offprint requests to: Dr. Michael Piper, School of Biomedical Sciences, The University of Queensland, Brisbane, 4072, Australia. e-mail: m.piper@uq.edu.au

DOI: 10.14670/HH-11-766

Glienke et al., 2002). *Crim1* genes are evolutionarily conserved in vertebrates including rodents and humans (Kolle et al., 2000), as well as zebrafish (Kinna et al., 2006), the chicken (Kolle et al., 2003) and *Xenopus* (Ponferrada et al., 2012). Interestingly, a Crim1 homolog called crm-1 has been described in *Caenorhabditis elegans* as well, although the role of this factor in the nematode has only received limited attention (Fung et al., 2007). Crim1 is expressed in various organs during embryogenesis, including the spinal cord, lens, kidney, vasculature and placenta (Kolle et al., 2000, 2003; Lovicu et al., 2000; Glienke et al., 2002; Pennisi et al., 2007, 2012; Phua et al., 2012; Fan et al., 2014), indicative of a role in their development. Structurally, the presence of six cysteine-rich repeat (CRR) motifs, an Insulin-like Growth Factor (IGF) Binding Protein (IGFBP) like domain and an arginyl-glycyl-aspartic acid motif (RGD) (Kolle et al., 2000) suggests that Crim1 can bind a variety of different proteins. In support of this, the CRRs have been shown to mediate the binding of CRIM1 to TGFβ, BMP, VEGF and PDGF when Crim1 is co-expressed in the same cell as the growth factor (Wilkinson et al., 2003, 2007). Recently, Crim1 has also been shown to interact with β1 Integrin via its RGD domain (Zhang et al., 2016). However, the functional

Abbreviations. BMP, Bone Morphogenetic Protein; Crim1, Cysteine-Rich Transmembrane BMP Regulator-1; CRR, Cysteine-rich Repeat, EMT, Epithelial-to-Mesenchymal Transition; EndoMT, Endothelial-to-Mesenchymal Transition; EPDC, Epicardium-Derived Cells; ERK, Extracellular signal-Regulated Kinase; FAK, Focal Adhesion Kinase; Gbb, Glass bottom boat; HUVEC, Human Umbilical Vein Endothelial Cell; IGF, Insulin-like Growth Factor; IGFBP, Insulin-like Growth Factor Binding Protein; NMJ, Neuromuscular Junction; PDGF, Platelet-Derived Growth Factor; PE, Proepicardium; RGD, arginyl-glycyl-aspartic acid motif; TGFβ, Transforming Growth Factor β; VEGF, Vascular Endothelial Growth Factor

significance of the IGFBP motif remains unknown. Interestingly, Crim1 has been demonstrated to localize in the endoplasmic reticulum and Golgi complex, where post translational modification of proteins are known to occur, and also the cell surface, where ligand-receptor interactions occur ((Glienke et al., 2002; Wilkinson et al., 2003), Pennisi lab, unpublished data).

The importance of proteins that regulate growth factor signalling has been highlighted by recent findings that implicate molecules containing multiple cysteine-rich regions, such as chordin and noggin, during development. For example, BMP signal transduction is regulated by various proteins that exert either a pro- or anti-BMP effect. Mediation of this pathway can occur at multiple levels, such as by sequestering BMPs and either facilitating or inhibiting BMP-receptor interactions, hindering BMP transport across cells and thus disturbing the BMP gradient required for downstream signaling, or by maintaining some BMPs in inactive form by preventing the cleavage of pre-BMPs and reducing the amount of mature, secreted BMPs (Wilkinson et al., 2003; Umulis et al., 2009). Chordin is an antagonist that directly binds BMPs (Larraín et al., 2000), and noggin, a cysteine-knot protein that binds BMPs and prevents them from binding to type I and type II cell surface BMPRs via masking of receptor binding sites (Zimmerman et al., 1996; Groppe et al., 2002). On the other hand, crossveinless-2 potentiates BMP signaling by forming a ternary complex with both chordin and BMP, and reduces the affinity of chordin for BMP, thus allowing BMPs to activate their downstream effectors via the BMPRs (Zhang et al., 2010). Importantly, the action of these proteins is dependent of the developmental context in which they, and the molecules they interact with, are expressed. This has been highlighted by *Crim1*-deficient mice, which exhibit phenotypes that indicate Crim1 can perform both agonistic and antagonistic functions on growth factor signaling during organogenesis.

To explore the role of Crim1 in development, a number of transgenic mice have been generated. Firstly, a genetrap line was created by random insertion of a β -geo cassette into intron 1 of the *Crim1* gene (called *Crim1*^{KST264}) (Leighton et al., 2001; Pennisi et al., 2007). Secondly, a conditional loss-of-function allele was generated (*Crim1*^{FLOX}), by flanking exons 3 and 4 of the *Crim1* gene with LoxP sites (Chiu et al., 2012). The *Crim1*^{FLOX} line, when crossed with the *CMV-Cre* deleter line, generated *Crim1*^{Afl^{ox}} mice, intercrosses from which produced mice lacking a functional *Crim1* gene (called *Crim1*^{Afl^{ox}/Afl^{ox}}) (Chiu et al., 2012). We have previously described perinatal lethality in mice homozygous for the *Crim1*^{KST264} genetrap and in *Crim1*^{Afl^{ox}/Afl^{ox}} mice (Pennisi et al., 2007; Chiu et al., 2012). Both strains display defects in multiple organ systems including the kidney, eye and placenta (Lovicu et al., 2000; Glienke et al., 2002; Pennisi et al., 2007, 2012; Phua et al., 2012; Fan et al., 2014), highlighting the importance of Crim1 during development. In this

review we discuss the role of Crim1 in organogenesis, with a specific focus on the developing heart, as well as providing mechanistic insight into how it can regulate the activity of growth factors.

The role of Crim1 in organogenesis

In the past 15 years a number of studies have begun to map the expression of Crim1 within the developing embryo, and have used the different transgenic mouse lines described above to decipher the role for Crim1 in organogenesis. A summary of these findings is detailed below.

Kidney

Perhaps the most widely studied organ in the context of Crim1 function is the kidney. In the embryonic murine kidney, Crim1 is expressed in pericytes lining the endothelium and within the parietal epithelial cells, mesangial cells and podocytes of the glomeruli from 15.5 days post coitum (dpc) (Georgas et al., 2000; Pennisi et al., 2007; Wilkinson et al., 2007). Studies of transgenic animals have provided significant insights into the role of Crim1 during kidney development. Kidneys from *Crim1*^{KST264/KST264} mice at 15.5 dpc were significantly smaller than their wild type littermates, indicating a role for Crim1 in nephrogenesis (Pennisi et al., 2007). Further analysis revealed multiple lesions in the glomerulus and glomerular capillary defects, and podocyte effacement (Wilkinson et al., 2007). In their elegant study, Wilkinson et al. showed Crim1 to be co-expressed with VEGF-A in the podocytes of the renal glomerulus. In mice lacking *Crim1*, there was an increased diffusion of VEGF-A away from the podocytes at 17.5 dpc, and a concomitant activation of the VEGF-A receptor Flk1 in adjacent vascular endothelial cells, supporting the observation of glomerular defects in these homozygous mice (Wilkinson et al., 2007). To assess whether renal abnormalities were present in the adult kidney, Wilkinson et al. made use of *Crim1*^{KST264/KST264} outbred mice, as a proportion of these homozygous animals survive to adulthood (Wilkinson et al., 2007). The kidneys of these adult mice displayed multiple glomerular cysts, interstitial fibrosis and endothelial cell thickening (Wilkinson et al., 2007), accompanied by further evidence of increased vascular leakiness and compromised extraglomerular vasculature (Wilkinson et al., 2009). Furthermore, a later study revealed renal fibrosis in *Crim1*^{KST264/KST264} adult mice along with endothelial aberrations, including an increase in vascular permeability and a discontinuous endothelium displaying abnormal collagen deposits (Phua et al., 2012). This could be due to the association of Crim1 with TGF β -1, which is known stimulate endothelial-to-mesenchymal transformation (EndoMT) (Kim et al., 2001; Varga and Wrana, 2005; Phua et al., 2012). In the adult human kidney, CRIM1 has been shown to be localized in the podocytes, both qualitatively, using renal

Crim1 in organogenesis

tissue in immunohistochemical experiments, and quantitatively, using immortalised human podocytes (Nyström et al., 2009), where BMPs and VEGFs are also expressed (Simon et al., 1995; Godin et al., 1999), indicating a possible role for CRIM1 in tethering these growth factors and releasing them into the local environment in a controlled manner.

Placenta

The placenta plays a central role during embryogenesis. It comprises a labyrinthine zone consisting of syncytiotrophoblast cells and junctional zone consisting of spongiotrophoblast and glycogen trophoblast cells. In mice, *Crim1* is expressed in various placental cell types including chorionic trophoblasts at 9.5 dpc, syncytiotrophoblasts at 13.5 and 15.5 dpc, and spongiotrophoblasts from 13.5 dpc (Pennisi et al., 2012). *Crim1* is important for placental development as, in the absence of this gene, placental size is reduced from 13.5 dpc until 17.5 dpc, with a consequent reduction in the size of *Crim1*^{KST264/KST264} embryos at the later stage (Pennisi et al., 2012). There is also a decrease in the number of sinusoidal-trophoblast giant cells and an increase in glycogen cells of *Crim1*^{KST264/KST264} placentae at 15.5 dpc, hypothesized to be due to a possible dysregulation of multiple signalling pathways (Pennisi et al., 2012), such as the IGF and VEGF pathways (Charnock-Jones et al., 1994; Randhawa and Cohen, 2005).

Lens and retinal vasculature

In the developing murine embryonic eye, *Crim1* expression is observed from 9.5 dpc until at least day postnatal day (P) 21 (Lovicu et al., 2000). Initially, *Crim1* is detected in the precursor to the lens, the lens placode, and subsequently is expressed by all lens cells by 11.5 dpc. *Crim1* transcripts are also present in the corneal epithelium and endothelium by 15.5 dpc, as well as the retinal epithelium and retinal ganglion cells at 18.5 dpc. At P21, *Crim1* expression persists only in the lens (Lovicu et al., 2000). Analysis of *Crim1*^{glcr11} (*glaucoma relevant 11*) mutants, termed so because of their glaucoma and cataract phenotype, reveals multiple lens defects that are evident from 16.5 dpc, including abnormal cell adhesion at epithelial adhesion junctions, disrupted polarity and a reduction in the number of proliferating lens epithelial cells, which collectively culminate in a smaller, atypical lens (Zhang et al., 2016). By P60, *Crim1* mutant mice also display lens cataracts and abnormal cellular proliferation within the retina. Mechanistically, the adhesion defects in these *Crim1* mutants are consistent with an interaction observed between *Crim1* and $\beta 1$ integrin, which is also expressed in both lens epithelial cells and lens fiber cells (Zhang et al., 2016). Indeed, analysis of $\beta 1$ integrin signalling reveals that *Crim1* regulates the phosphorylation status of its downstream effectors focal adhesion kinase (FAK)

and extracellular signal-regulated kinase (ERK), resulting in modulation of lens morphogenesis by membrane-bound *Crim1* (Zhang et al., 2016).

As *Crim1* is expressed *in vivo* and *in vitro* in vascular endothelial cells (Glienke et al., 2002), and in the vasculature of the embryonic mouse hindbrain and postnatal retinas (Fan et al., 2014), its role in the retinal vasculature has also been analysed. Crossing the *Crim1*^{Flox} allele to *Pdgfrb-iCreER* mice to enable inducible deletion of *Crim1* from endothelial cells reveals that defective retinal vascular development occurs in the absence of *Crim1* from the vasculature (Fan et al., 2014). The phenotypes observed included reduced vessel density, length and branchpoint number, and vessel regression in the first week of postnatal development (Fan et al., 2014). Indeed, these authors revealed modulation of the autocrine activity of VEGF-A by *Crim1*, indicating that it has an important regulatory role in the formation and development of the vasculature (Fan et al., 2014). The distribution of the cell adhesion molecule VE-Cadherin at the angiogenic front of *Crim1*^{Flox/flox}; *Pdgfrb-iCreER* retinal vasculature preparations was also altered (Fan et al., 2014), a finding consistent with the impaired endothelial tube formation evident in HUVECs in the absence of CRIM1 (Glienke et al., 2002). This is suggestive of a cell adhesion anomaly. A possible role for the conserved RGD motif in *Crim1* in this context is possible, as this domain of *Crim1* potentially binds integrins and so modulates cellular attachment (Kolle et al., 2000). The intracellular domain of *Crim1* could also play a role in cell adhesion, as the cytoplasmic domain of *Crim1* has been shown to indirectly bind β -catenin and N-cadherin in *Xenopus* (Ponferrada et al., 2012).

Nervous system

Preliminary investigations have also shown that *Crim1* may be important for the development of the nervous system. For instance, in the developing mouse spinal cord, *Crim1* is expressed from 9.5 dpc in the floor plate, and in pools of motor neurons at later stages of development (Kolle et al., 2000). Moreover, *Crim1* expression is observed in other regions of the nascent mouse neuraxis, including the forebrain and hindbrain from 11.5 dpc, and in the midbrain at 13.5dpc (Kolle et al., 2000). Despite this, studies have yet to elucidate the mechanistic function of *Crim1* in the developing nervous system. Looking forwards, using our understanding of the role of *Crim1* in other developmental contexts may provide insights into the role of this factor within the developing nervous system. For example, the colocalization of *Crim1* and $\beta 1$ integrins at the leading edges of lens epithelial cell projections regulates cell adhesion and polarity (Zhang et al., 2016). As cellular adhesion and polarity are critical components that underlie the proliferation and subsequent differentiation of neural stem cells within the embryonic brain, a role for *Crim1* in mediating these aspects during neural

development is plausible.

The role of *Crim1* in cardiac development

Overview of organogenesis of the heart

Another organ in which *Crim1* plays an important role during development is the heart. The heart is the first organ to form and function in the vertebrate embryo (Yutzey and Kirby, 2002), and cardiac progenitor cells are among the earliest to migrate through the primitive streak during gastrulation (Garcia-Martinez and Schoenwolf, 1993; Schoenwolf and Garcia-Martinez, 1995). Splanchnic mesenchymal cells, the principal cardiac precursors, arise from primary heart fields in the lateral plate mesoderm (Waldo et al., 2001) and aggregate in the cardiogenic region to form angioblastic cords. These canalize to form two thin-walled endocardial heart tubes. Their subsequent fusion forms a single two-layered heart tube (Manasek, 1969) comprising the outer mesenchymal myocardial mantle which forms the myocardium, and the inner endothelial tube which forms the endocardium, separated by myocardium-produced cardiac jelly (Waldo et al., 1999).

The epicardium of the heart develops from a transient structure, the proepicardium (PE) (Virágh and Challice, 1981; Männer, 1993; Virágh et al., 1993; Gittenberger-de Groot et al., 1998), that is located between the sinus horns and liver primordium (Virágh et al., 1993), and which is derived from the lateral plate mesoderm (Serluca, 2008). The PE contains smooth muscle, fibroblast and endothelial progenitors (Mikawa and Gourdie, 1996; Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Männer, 1999; Pérez-Pomares et al., 2002), but whether it is the sole contributor of endothelial cells to the coronary vasculature is contentious, as the liver bud and sinus venosus have also been suggested as sources of the same (Poelmann et al., 1993; Ishii et al., 2007; Red-Horse et al., 2010; Cossette and Misra, 2011).

Proepicardial cells attach to the inner curvature of the atrioventricular junction of the rudimentary heart (Männer, 1993; Ishii et al., 2010) to form its outermost layer – the epicardium. Species-specific migration of proepicardial cells to the myocardium occurs either by proepicardial vesicle budding or via an extracellular matrix bridge to potentially guide the translocation (Nahirney et al., 2003). It has been suggested that the proximity between the liver bud and the PE affects proepicardial attachment to the heart and differentiation via an associated effect on proepicardial marker genes (Ishii et al., 2007). Following the attachment, a population of epicardial cells undergo EMT to form subepicardial cells, including those contributing to the subepicardial coronary vasculature, whereas another subset of these cells traverse the subepicardial space and migrate into the myocardium (Virágh and Challice, 1981) to give rise to various cell types, including coronary vascular smooth muscle cells, coronary vascular endothelial cells and cardiac fibroblasts (Virágh

and Challice, 1981; Männer, 1993; Virágh et al., 1993; Mikawa and Gourdie, 1996; Gittenberger-de Groot et al., 1998).

Crim1 and cardiac development

What evidence is there that *Crim1* plays a role in cardiac development? Firstly, studies on the *Crim1*^{KST264} genetrap line (which carries a LacZ reporter), have shown that *Crim1*-promoter mediated LacZ expression is evident in the murine proepicardium at 9.5 dpc, and within the epicardium throughout cardiac development. It is also observed in coronary vascular smooth muscle cells and, to a weaker extent, in coronary vascular endothelial cells, at later stages of heart development (Pennisi et al., 2007). LacZ expression is also observed in the outflow tract mesenchyme, bicuspid and tricuspid valve leaflets and atrial septum at 18.5 dpc (Iyer et al., 2016). These sites of expression imply that *Crim1* may regulate many aspects of cardiac development. Interestingly, there are many cardiac phenotypes, such as chamber septation and valve defects, hypoplastic ventricular walls and coronary vasculature defects, that arise as a result of dysregulation of growth factors such including TGFβs, BMPs, VEGFs and IGFs (Kim et al., 2001; Chen et al., 2004; Goldman et al., 2009; Uchimura et al., 2009; Li et al., 2011; Wu et al., 2012). This indicates that growth factor activity is normally tightly controlled during cardiogenesis. Given the interaction of *Crim1* with many of these factors in other organ systems, and preliminary data indicating that *Crim1* mutant cardiac phenotypes are reminiscent of these phenotypes, we posit that *Crim1* mediates cardiogenesis, at least in part, via the regulation of growth factor signalling.

For example, epicardial EMT is a vital process that occurs during normal heart development, and several growth factors have been implicated in both EMT, and the differentiation of epicardial cells into their correct lineages. A number of distinct molecular processes work cooperatively in order to initiate and promote epicardial EMT. As the heart develops, there is significant cross-talk between the epicardium and myocardium, with epicardial signalling via its secreted factors and epicardium-derived cells, as well as signalling from the myocardium, being essential for myocardial growth and differentiation (Sucov et al., 2009) and coronary vascular development (Kang and Sucov, 2005). Thus, it is this reciprocal signalling between the epicardium and myocardium which provides cues to ensure the proper and timely differentiation of epicardial lineages, maturation of the myocardium and the coronary vasculature, and, ultimately, the development and functioning of the heart. For instance, TGFβs stimulate epicardial EMT (Dokic and Dettman, 2006; Olivey et al., 2006; Sánchez and Barnett, 2012). Binding of TGFβ2 and TGFβ3 to TGFβR2, and the subsequent activation of TGFβR1, leads to the phosphorylation of SMAD2/3 proteins and upregulation of transcription factors such as *snail1* and *slug*. These factors repress the expression of

E-cadherin, while promoting the expression of Vimentin, RhoA and various ECM molecules (Xu et al., 2009), thus facilitating a transition away from epithelial characteristics. Using the *WT1-Cre* and *WT1-CreERT2* cell lines, we have shown that EMT and epicardial migration are increased in the absence of *Crim1* (Iyer et al., 2016). The epicardium of *Crim1* null mutant hearts surprisingly shows a reduced phospho-SMAD2 level, indicative of reduced TGF β signalling (Iyer et al., 2016), at 13.5 dpc, despite enhanced EMT. This indicates that there could be a role for *Crim1* in the formation or stabilization of cadherin-dependent junctional complexes in epithelial cells, via which it could serve to normally restrain epicardial EMT. β -catenin is a crucial component of adherens junctions, and has been previously shown to complex indirectly with *Crim1* (Ponferrada et al., 2012). Indeed, assessment of β -Catenin distribution at epicardial cell-cell junctions is altered in *Crim1*-deficient mice, indicating a loss of stability at these contact points within the developing heart (Iyer et al., 2016).

Epithelial and mesenchymal cells secrete PDGF-A, which may act as a mitogen that stimulates ventricular development and cardiomyocyte proliferation (Kang et al., 2008). Moreover, PDGF-B can stimulate proepicardial cells expressing smooth muscle markers to undergo epicardial EMT and subsequently commit to the coronary smooth muscle cell lineage, mediated through PDGFR- β (Lu et al., 2001), while PDGFR- α plays an important role in the formation of cardiac fibroblasts (Smith et al., 2011). Both PDGF receptors are implicated in EMT, whereby epicardium-derived cells (EPDCs) give rise to myocardial fibroblasts and vascular smooth muscle cells (Mellgren et al., 2008; Smith et al., 2011). We have recently reported a reduction in the number of EPDC-derived myocardial fibroblasts within *Crim1* mutant mice (Iyer et al., 2016). Although *Crim1* has been shown to be capable of binding PDGF-B (Wilkinson et al., 2007), direct evidence to support a role of *Crim1* in the modulation of this pathway in the heart is currently lacking. Future work aimed at investigating this exciting prospect will undoubtedly advance our understanding of the mechanism through which *Crim1* regulates the biology of EPDC-derived cells. Moreover, PDGF-B is also expressed by endothelial cells and is required for the endothelial-cell-mediated recruitment for coronary vascular smooth muscle cells to the developing coronary vessels (Van den Akker et al., 2008). Given the nature of the *Crim1* protein, this cysteine-knot protein could also potentially antagonise this aspect of cardiac development by tethering PDGFs to the cell surface and limiting their action, another fruitful avenue of future research.

Interestingly, in support of this hypothesis, Wilkinson et al. previously identified that *Crim1* potentially functions as an antagonistic regulator of certain members of the BMP family. *Crim1* interacts intracellularly with both BMP4 and BMP7 (Wilkinson et al., 2003), and co-localizes with their respective pre-

BMPs within the golgi via its CRRs, ultimately reducing the secretion of mature BMPs. Furthermore, a proportion of the BMPs released remain bound to *Crim1* (Wilkinson et al., 2003). *Crim1* has also been implicated in tethering BMPs to the cell, which may serve to restrict their functional potential, and, since BMPs are known to act across a restricted distance (Jones et al., 1996), possibly to act in the presentation of BMP ligands to neighbouring cells. BMPs are well known for their role in cardiac development. For instance, BMP2 increases epicardial EMT via TGF β 3 activation in epicardial cell lines (Sánchez and Barnett, 2012), and BMP4 has been shown to play an important role in both atrioventricular and outflow tract septation (Jiao et al., 2003; Liu et al., 2004). The absence of *Bmp10* leads to impaired ventricular trabeculation and formation of thin ventricular walls (Neuhaus et al., 1999), a phenotype recapitulated in mice lacking both *Bmp6* and *Bmp7* (Kim et al., 2001). Given the need for exquisite spatial and temporal modulation of BMP signaling, it is likely that *Crim1* also regulates this family of molecules during cardiac development. Indeed, hypoplastic ventricles are observed in *Crim1* null mice, alongside a concomitant increase in apoptosis of intramural cells, indicating that *Crim1* is necessary for the formation of the myocardium, potentially via the modulation of BMP signalling (Iyer et al., 2016). The use of next generation sequencing in *Crim1*-deficient mice, coupled with proteomic approaches, could provide a future avenue to determine the role *Crim1* plays in the modulation of BMP biology during cardiac development.

IGFs have been also implicated as epicardial mitogenic factors during heart formation. For instance, IGF-2 is secreted from the epicardium and exerts a mitogenic effect on the formation of the compact myocardium (Li et al., 2011). Could the IGFBP motif of *Crim1*, along with the CRR domains, bind IGFs and regulate their activity? Interestingly, there is an increase in ERK1/2 signalling in the myocardium of *Crim1*-deficient hearts at 13.5 dpc (Iyer et al., 2016). This indicates that *Crim1* regulates signalling molecules secreted by the epicardium, or by the myocardium itself, and is thus essential for myocardial maturation in the early stages of heart development. A large number of growth factors are known to activate the ERK pathway, including IGFs, and downstream ERK signalling can be both pro- and anti-apoptotic, making it important to identify which growth factors are specifically involved in this process, and exactly how this augmented ERK1/2 signalling affects the development of the myocardium. It would thus be useful to assess whether *Crim1* can indeed bind IGFs, and further whether *Crim1* can modulate this important growth factor in the context of the developing heart.

Concluding remarks

While the broad role of *Crim1* in developmental organogenesis is now well established, much remains

unclear as to how this transmembrane protein exerts its biological influence. Critically, the mechanisms by which Crim1 mediates growth factor signalling in different developmental contexts are still poorly defined. For example, in *C. elegans*, crm-1 acts as an agonist of a BMP-like pathway, the DBL-1 pathway, in a non-cell-autonomous fashion (Fung et al., 2007), although it is not known whether this occurs through an interaction with the ligand or its receptor. In contrast to this agonistic role with regards to BMP signalling, the *Drosophila* homolog of Crim1, CRIMPY, antagonizes the function of the BMP ligand Glass bottom boat (Gbb) in motorneurons at the neuromuscular junction (NMJ), and restrains the expansion of the NMJ (James and Broihier, 2011). The full-length Gbb precursor associates preferentially with the extracellular domain of CRIMPY to regulate synaptic development, before Gbb is secreted from the motorneuron terminal (James and Broihier, 2011). Similarly, Crim1 binds to and antagonistically modulates the processing of pre-BMPs and the secretion of mature BMPs in COS7 cells (Wilkinson et al., 2003). These findings highlight the fact that the function of Crim1 in organogenesis is context-dependent, and that the timing and site of Crim1 expression, coupled with that of the multitude of growth factors it can potentially interact with, will influence its biological function.

Looking to the future, investigations into Crim1 function during development will enable us to probe the mechanisms underlying a variety of pathological disorders. For instance, the adult myocardium has limited regenerative capacity. New technologies have made the generation of cardiomyocytes from induced stem cells a possibility, but it remains essential to clarify the growth factors and signalling molecules germane to this process to make this feasible. BMPs, for instance, regulate stem cell renewal and differentiation into cardiomyocytes, and cooperate with other signalling pathways to further modulate gene expression of transcription factors (Varga and Wrana, 2005; van Wijk et al., 2007). As Crim1 can regulate BMP processing, investigating the intersection between Crim1 biology and BMP signalling during the generation of cardiomyocytes *in vitro* could be a valuable approach. Similarly, research on the reactivation of the adult epicardium following myocardial damage has increased in recent years, and the modulation of growth factors such as BMPs, TGF β , VEGF and PDGF by Crim1 is an attractive avenue of research that remains to be explored. Moreover, as myocardial injury stimulates epicardial cells to give rise to fibroblasts and smooth muscle cells (Limana et al., 2011; Zhou et al., 2011; Duan et al., 2012; Huang et al., 2012; van Wijk et al., 2012), our recent observation that, in the absence of *Crim1*, the number of cardiac fibroblasts is reduced (Iyer et al., 2016), is another step towards deciphering its role not only in lineage specification but also potential therapeutic interventions to improve cardiac performance after damage.

With relation to other pathological disorders, the

analysis of serum from chronic heart failure patients shows an increase in CRIM1 levels, along with an increase in secreted factors involved in fibrosis, indicating a positive correlation between CRIM1 and pro-fibrotic activity (Eleuteri et al., 2014), though whether these increases are reflected within cardiac tissue is not clear. Moreover, CRIM1 is expressed at higher levels in drug-resistant leukaemia cells, implicating it as a potential drug resistance marker (Prekert et al., 2010). The intronic regions of *CRIM1* and *ZEB2* have been demonstrated to be downregulated in breast cancer epithelial cells (Kim et al., 2015), and *CRIM1* has also been suggested to be a target of the Hippo pathway, and to be overexpressed in gastric cancer tissues (Lim et al., 2014). These tantalising vignettes into the role of CRIM1 in cancer biology and disease provide a platform on which to further investigate the role of this gene in pathological conditions. Indeed, studies from development have illustrated that Crim1 may act at the nexus of many critical signalling pathways, and so the manipulation of *Crim1* expression may provide a parsimonious mechanism by which cellular functions such as proliferation, differentiation and repair can be efficiently manipulated following injury and tumorigenesis.

Acknowledgements. This work was funded by grants from the National Health and Medical Research Council to MP (1057751) and DJP (631658). MP holds an Australian Research Council Future Fellowship (FT120100170). SI was supported by a UQ Research Scholarship. We gratefully acknowledge Dr. Diane Maresco-Pennisi for reading preliminary drafts of the review.

References

- Charnock-Jones D.S., Sharkey A.M., Boocock C.A., Ahmed A., Plevin R., Ferrara N. and Smith S.K. (1994). Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. *Biol. Reprod.* 51, 524-530.
- Chen H., Shi S., Acosta L., Li W., Lu J., Bao S., Chen Z., Yang Z., Schneider M.D., Chien K.R., Conway S.J., Yoder M.C., Haneline L.S., Franco D. and Shou W. (2004). Bmp10 is essential for maintaining cardiac growth during murine cardiogenesis. *Development* 131, 2219-2231.
- Chiu H.S., York J.P., Wilkinson L., Zhang P., Little M.H. and Pennisi D.J. (2012). Production of a mouse line with a conditional *crim1* mutant allele. *Genesis* 50, 711-716.
- Cossette S. and Misra R. (2011). The identification of different endothelial cell populations within the mouse proepicardium. *Dev. Dyn.* 240, 2344-2353.
- Dettman R.W., Denetclaw W. Jr, Ordahl C.P. and Bristow J. (1998). Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. *Dev. Biol.* 193, 169-181.
- Dokic D. and Dettman R.W. (2006). Vcam-1 inhibits tgfbeta stimulated epithelial-mesenchymal transformation by modulating rho activity and stabilizing intercellular adhesion in epicardial mesothelial cells. *Dev. Biol.* 299, 489-504.

Crim1 in organogenesis

- Duan J., Gherghe C., Liu D., Hamlett E., Srikantha L., Rodgers L., Regan J.N., Rojas M., Willis M., Leask A., Majesky M. and Deb A. (2012). Wnt1/ β catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. *EMBO J.* 31, 429-442.
- Eleuteri E., Di Stefano A., Vallese D., Gnemmi I., Pitruzzella A., Tarro Genta F., Delle Donne L., Cappello F., Ricciardolo F.L. and Giannuzzi P. (2014). Fibrosis markers and *crim1* increase in chronic heart failure of increasing severity. *Biomarkers* 19, 214-221.
- Fan J., Ponferrada V.G., Sato T., Vemaraju S., Fruttiger M., Gerhardt H., Ferrara N. and Lang R.A. (2014). *Crim1* maintains retinal vascular stability during development by regulating endothelial cell vegfa autocrine signaling. *Development* 141, 448-459.
- Fung W.Y., Fat K.F., Eng C.K. and Lau C.K. (2007). *Crm-1* facilitates bmp signaling to control body size in *Caenorhabditis elegans*. *Dev. Biol.* 311, 95-105.
- Garcia-Martinez V. and Schoenwolf G.C. (1993). Primitive-streak origin of the cardiovascular system in avian embryos. *Dev. Biol.* 159, 706-719.
- Georgas K., Bowles J., Yamada T., Koopman P. and Little M.H. (2000). Characterisation of *crim1* expression in the developing mouse urogenital tract reveals a sexually dimorphic gonadal expression pattern. *Dev. Dyn.* 219, 582-587.
- Gittenberger-de Groot A.C., Vrancken Peeters M.P., Mentink M.M., Gourdie R.G. and Poelmann R.E. (1998). Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. *Circ. Res.* 82, 1043-1052.
- Glienke J., Sturz A., Menrad A. and Thierach K.H. (2002). *Crim1* is involved in endothelial cell capillary formation *in vitro* and is expressed in blood vessels *in vivo*. *Mech. Dev.* 119, 165-175.
- Godin R.E., Robertson E.J. and Dudley A.T. (1999). Role of bmp family members during kidney development. *Int. J. Dev. Biol.* 43, 405-411.
- Goldman D.C., Donley N. and Christian J.L. (2009). Genetic interaction between *bmp2* and *bmp4* reveals shared functions during multiple aspects of mouse organogenesis. *Mech. Dev.* 126, 117-127.
- Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., Affolter M., Vale W.W., Belmonte J.C. and Choe S. (2002). Structural basis of bmp signalling inhibition by the cystine knot protein noggin. *Nature* 420, 636-642.
- Huang G.N., Thatcher J.E., McAnally J., Kong Y., Qi X., Tan W., DiMaio J.M., Amatruda J.F., Gerard R.D., Hill J.A., Bassel-Duby R. and Olson E.N. (2012). *C/ebp* transcription factors mediate epicardial activation during heart development and injury. *Science* 338, 1599-1603.
- Ishii Y., Langberg J.D., Hurtado R., Lee S. and Mikawa T. (2007). Induction of proepicardial marker gene expression by the liver bud. *Development* 134, 3627-3637.
- Ishii Y., Garriock R.J., Navetta A.M., Coughlin L.E. and Mikawa T. (2010). Bmp signals promote proepicardial protrusion necessary for recruitment of coronary vessel and epicardial progenitors to the heart. *Dev. Cell* 19, 307-316.
- Iyer S., Chou F.Y., Wang R., Chiu H.S., Raju V.K.S., Little M.H., Thomas W.G., Piper M. and Pennisi D.J. (2016). *Crim1* has cell-autonomous and paracrine roles during embryonic heart development. *Sci. Rep.* 6, 19832.
- James R.E. and Broihier H.T. (2011). *Crimpy* inhibits the bmp homolog *gbb* in motoneurons to enable proper growth control at the *Drosophila* neuromuscular junction. *Development* 138, 3273-3286.
- Jiao K., Kulesa H., Tompkins K., Zhou Y., Batts L., Baldwin H.S. and Hogan B.L. (2003). An essential role of *bmp4* in the atrioventricular septation of the mouse heart. *Genes Dev.* 17, 2362-2367.
- Jones C.M., Armes N. and Smith J.C. (1996). Signalling by *tgf- β* family members: Short-range effects of *xnr-2* and *bmp-4* contrast with the long-range effects of activin. *Curr. Biol.* 6, 1468-1475.
- Kang J., Gu Y., Li P., Johnson B.L., Sucov H.M. and Thomas P.S. (2008). PDGF-A as an epicardial mitogen during heart development. *Dev. Dyn.* 237, 692-701.
- Kang J.O. and Sucov H.M. (2005). Convergent proliferative response and divergent morphogenic pathways induced by epicardial and endocardial signaling in fetal heart development. *Mech. Dev.* 122, 57-65.
- Kim R.Y., Robertson E.J. and Solloway M.J. (2001). BMP6 and BMP7 are required for cushion formation and septation in the developing mouse heart. *Dev. Biol.* 235, 449-466.
- Kim S.W., Fishilevich E., Arango-Argoty G., Lin Y., Liu G., Li Z., Monaghan A.P., Nichols M. and John B. (2015). Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense rnas. *PLoS One* 10, e0120296.
- Kinna G., Kolle G., Carter A., Key B., Lieschke G.J., Perkins A. and Little M.H. (2006). Knockdown of zebrafish *crim1* results in a bent tail phenotype with defects in somite and vascular development. *Mech. Dev.* 123, 277-287.
- Kolle G., Jansen A., Yamada T. and Little M. (2003). *In ovo* electroporation of *crim1* in the developing chick spinal cord. *Dev. Dyn.* 226, 107-111.
- Kolle G., Georgas K., Holmes G.P., Little M.H. and Yamada T. (2000). *Crim1*, a novel gene encoding a cysteine-rich repeat protein, is developmentally regulated and implicated in vertebrate CNS development and organogenesis. *Mech. Dev.* 90, 181-193.
- Larrain J., Bachiller D., Lu B., Agius E., Piccolo S. and De Robertis E.M. (2000). Bmp-binding modules in chordin: A model for signalling regulation in the extracellular space. *Development* 127, 821-830.
- Leighton P.A., Mitchell K.J., Goodrich L.V., Lu X., Pinson K., Scherz P., Skarnes W.C. and Tessier-Lavigne M. (2001). Defining brain wiring patterns and mechanisms through gene trapping in mice. *Nature* 410, 174-179.
- Li P., Cavellero S., Gu Y., Chen T.H.P., Hughes J., Bassim Hassan A., Bruning J.C., Pashmforoush M. and Sucov H.M. (2011). Igf signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. *Development* 138, 1795-1805.
- Lim B., Park J.L., Kim H.J., Park Y.K., Kim J.H., Sohn H.A., Noh S.M., Song K.S., Kim W.H., Kim Y.S. and Kim S.Y. (2014). Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of *tead4* in gastric cancer. *Carcinogenesis* 35, 1020-1027.
- Limana F., Capogrossi M.C. and Germani A. (2011). The epicardium in cardiac repair: From the stem cell view. *Pharmacol. Therapeut.* 129, 82-96.
- Liu W., Selever J., Wang D., Lu M.F., Moses K.A., Schwartz R.J. and Martin J.F. (2004). Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling. *PNAS* 101, 4489-4494.
- Lovicu F.J., Kolle G., Yamada T., Little M.H. and McAvoy J.W. (2000). Expression of *crim1* during murine ocular development. *Mech. Dev.* 94, 261-265.
- Lu J., Landerholm T.E., Wei J.S., Dong X.R., Wu S.P., Liu X., Nagata K., Inagaki M. and Majesky M.W. (2001). Coronary smooth muscle differentiation from proepicardial cells requires rhoa-mediated actin reorganization and p160 rho-kinase activity. *Dev. Biol.* 240, 404-418.

Crim1 in organogenesis

- Manasek F.J. (1969). Embryonic development of the heart. II. Formation of the epicardium. *JEEM* 22, 333-348.
- Männer J. (1993). Experimental study on the formation of the epicardium in chick embryos. *Anat. Embryol.* 187, 281-289.
- Männer J. (1999). Does the subepicardial mesenchyme contribute myocardioblasts to the myocardium of the chick embryo heart? A quail-chick chimera study tracing the fate of the epicardial primordium. *Anat. Rec.* 255, 212-226.
- Mellgren A.M., Smith C.L., Olsen G.S., Eskiocak B., Zhou B., Kazi M.N., Ruiz F.R., Pu W.T. and Tallquist M.D. (2008). Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. *Circ. Res.* 103, 1393-1401.
- Mikawa T. and Gourdie R.G. (1996). Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. *Dev. Biol.* 174, 221-232.
- Nahrney P.C., Mikawa T. and Fischman D.A. (2003). Evidence for an extracellular matrix bridge guiding proepicardial cell migration to the myocardium of chick embryos. *Dev. Dyn.* 227, 511-523.
- Neuhaus H., Rosen V. and Thies R.S. (1999). Heart specific expression of mouse *bmp-10* a novel member of the *tgf-beta* superfamily. *Mech. Dev.* 80, 181-184.
- Nyström J., Hulténby K., Ek S., Sjölund J., Axelson H., Jirström K., Saleem M.A., Nilsson K. and Johansson M.E. (2009). *Crim1* is localized to the podocyte filtration slit diaphragm of the adult human kidney. *Neph. Dial. Transplant.* 24, 2038-2044.
- Olivey H.E., Mundell N.A., Austin A.F. and Barnett J.V. (2006). Transforming growth factor- β stimulates epithelial-mesenchymal transformation in the proepicardium. *Dev. Dyn.* 235, 50-59.
- Pennisi D.J., Kinna G., Chiu H.S., Simmons D.G., Wilkinson L. and Little M.H. (2012). *Crim1* has an essential role in glycogen trophoblast cell and sinusoidal-trophoblast giant cell development in the placenta. *Placenta* 33, 175-182.
- Pennisi D.J., Wilkinson L., Kolle G., Sohaskey M.L., Gillinder K., Piper M.J., McAvoy J.W., Lovicu F.J. and Little M.H. (2007). *Crim1* complexed with β -catenin and cadherins, stabilizes cell-cell junctions and is critical for neural morphogenesis. *PLoS One* 7, e32635.
- Ponferrada V.G., Fan J., Vallance J.E., Hu S., Mamedova A., Rankin S.A., Kofron M., Zorn A.M., Hegde R.S. and Lang R.A. (2012). *Crim1* complexes with β -catenin and cadherins, stabilizes cell-cell junctions and is critical for neural morphogenesis. *PLoS One* 7, e32635.
- Prenkert M., Uggla B., Tidefelt U. and Strid H. (2010). *Crim1* is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia hl60 cells. *Anticancer Res.* 30, 4157-4161.
- Randhawa R. and Cohen P. (2005). The role of the insulin-like growth factor system in prenatal growth. *Mol. Genet. Metab.* 86, 84-90.
- Red-Horse K., Ueno H., Weissman I.L. and Krasnow M.A. (2010). Coronary arteries form by developmental reprogramming of venous cells. *Nature* 464, 549-553.
- Sánchez N.S. and Barnett J.V. (2012). TGF β and BMP-2 regulate epicardial cell invasion via TGF β activation of the *par6/smurf1/rhoA* pathway. *Cell Signal.* 24, 539-548.
- Schoenwolf G.C. and Garcia-Martinez V. (1995). Primitive-streak origin and state of commitment of cells of the cardiovascular system in avian and mammalian embryos. *Cell. Mol. Biol. Res.* 41, 233-240.
- Serluca F.C. (2008). Development of the proepicardial organ in the zebrafish. *Dev. Biol.* 315, 18-27.
- Simon M., Grone H.J., Johren O., Kullmer J., Plate K.H., Risau W. and Fuchs E. (1995). Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. *Am. J. Physiol.* 268, F240-250.
- Smith C.L., Baek S.T., Sung C.Y. and Tallquist M.D. (2011). Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require *pdgf* receptor signaling. *Circ. Res.* 108, e15-e26.
- Sucov H.M., Gu Y., Thomas S., Li P. and Pashmforoush M. (2009). Epicardial control of myocardial proliferation and morphogenesis. *Pediatr. Cardiol.* 30, 617-625.
- Uchimura T., Komatsu Y., Tanaka M., McCann K.L. and Mishina Y. (2009). *Bmp2* and *bmp4* genetically interact to support multiple aspects of mouse development including functional heart development. *Genesis* 47, 374-384.
- Umulis D., O'Connor M.B. and Blair S.S. (2009). The extracellular regulation of bone morphogenetic protein signaling. *Development* 136, 3715-3728.
- Van den Akker N.M., Winkel L.C., Nisancioglu M.H., Maas S., Wisse L.J., Armulik A., Poelmann R.E., Lie-Venema H., Betsholtz C. and Gittenberger-de Groot A.C. (2008). *Pdgf-b* signaling is important for murine cardiac development: Its role in developing atrioventricular valves, coronaries, and cardiac innervation. *Dev. Dyn.* 237, 494-503.
- van Wijk B., Moorman A.F. and van den Hoff M.J. (2007). Role of bone morphogenetic proteins in cardiac differentiation. *Cardiovasc. Res.* 74, 244-255.
- van Wijk B., Gunst Q.D., Moorman A.F.M. and van den Hoff M.J.B. (2012). Cardiac regeneration from activated epicardium. *PLoS One* 7, e44692.
- Varga A.C. and Wrana J.L. (2005). The disparate role of BMP in stem cell biology. *Oncogene* 24, 5713-5721.
- Virágh S. and Challice C.E. (1981). The origin of the epicardium and the embryonic myocardial circulation in the mouse. *Anat. Rec.* 201, 157-168.
- Virágh S., Gittenberger-de Groot A.C., Poelmann R.E. and Kálmán F. (1993). Early development of quail heart epicardium and associated vascular and glandular structures. *Anat. Embryol.* 188, 381-393.
- Waldo K., Zdanowicz M., Burch J., Kumiski D.H., Stadt H.A., Godt R.E., Creazzo T.L. and Kirby M.L. (1999). A novel role for cardiac neural crest in heart development. *J. Clin. Invest.* 103, 1499-1507.
- Waldo K.L., Kumiski D.H., Wallis K.T., Stadt H.A., Hutson M.R., Platt D.H. and Kirby M.L. (2001). Conotruncal myocardium arises from a secondary heart field. *Development* 128, 3179-3188.
- Wilkinson L., Kolle G., Wen D., Piper M., Scott J. and Little M. (2003). *Crim1* regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. *J. Biol. Chem.* 278, 34181-34188.

Crim1 in organogenesis

- Wilkinson L., Gilbert T., Kinna G., Ruta L.A., Pennisi D., Kett M. and Little M.H. (2007). *Crim1*^{kst264/kst264} mice implicate *crim1* in the regulation of vascular endothelial growth factor- α activity during glomerular vascular development. *J. Amer. Soc. Nephrol.* 18, 1697-1708.
- Wilkinson L., Gilbert T., Sipos A., Toma I., Pennisi D.J., Peti-Peterdi J. and Little M.H. (2009). Loss of renal microvascular integrity in postnatal *crim1* hypomorphic transgenic mice. *Kidney Int.* 76, 1161-1171.
- Wu B., Zhang Z., Lui W., Chen X., Wang Y., Chamberlain A., Moreno-Rodriguez R.A., Markwald R.R., O'Rourke B.P., Sharp D.J., Zheng D., Lenz J., Baldwin H.S., Chang C.-P. and Zhou B. (2012). Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial vegf signaling. *Cell* 151, 1083-1096.
- Xu J., S. Lamouille and R. Derynck (2009). TGF- β -induced epithelial to mesenchymal transition. *Cell Res.* 19, 156-172.
- Yutzey K.E. and Kirby M.L. (2002). Wherefore heart thou? Embryonic origins of cardiogenic mesoderm. *Dev. Dyn.* 223, 307-320.
- Zhang J.L., Patterson L.J., Qiu L.Y., Graziussi D., Sebald W. and Hammerschmidt M. (2010). Binding between crossveinless-2 and chordin von willebrand factor type c domains promotes bmp signaling by blocking chordin activity. *PLoS One* 5, e12846.
- Zhang Y., Fan J., Ho J.W.K., Hu T., Kneeland S.C., Fan X., Xi Q., Sellarole M.A., de Vries W.N., Lu W., Lachke S.A., Lang R.A., John S.W.M. and Maas R.L. (2016). *Crim1* regulates integrin signaling in murine lens development. *Development* 143, 356-366.
- Zhou B., Honor L.B., He H., Ma Q., Oh J.H., Butterfield C., Lin R.Z., Melero-Martin J.M., Dolmatova E., Duffy H.S., Gise A., Zhou P., Hu Y.W., Wang G., Zhang B., Wang L., Hall J.L., Moses M.A., McGowan F.X. and Pu W.T. (2011). Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. *J. Clin. Invest.* 121, 1894-1904.
- Zimmerman L.B., De Jesus-Escobar J.M. and Harland R.M. (1996). The spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* 86, 599-606.

Accepted April 5, 2016